Sign inJoin free

Watch / Small Cap

Richards' stock picks | Cyclopharma's FDA nod | Moors small comeback

2 Oct 202327:39

Richards' stock picks | Cyclopharma's FDA nod | Moors small comeback

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Ben Richards of Seneca Financial Solutions points out a potential uptick in small caps in the market, highlighting a possible end to their recent downward trajectory. He notes that there is a surge in corporate activities across diverse industries, specially in small and micro caps. This surge, considers Ben, is primarily due to over-selling of small caps, which has paved the way for heightened activity among traders and private finance buyers. There's a chance, Ben states, to capitalise on these activities by investing in small caps and diversifying the portfolio. He emphasises that small cap stocks hold unique risks and opportunities which are not as dependent on macro-economic indicators as their larger counterparts. Ben maintains that these distinct factors potentially render the small caps segment an appealing option for investors.

Cyclopharm (CYC) CEO James McBrayer discusses the FDA approval of their Technegas technology, set to enter the estimated $180 million U.S. market annually for managing pulmonary embolism. The Australian-based technology, present in 64 countries, anticipates dominating the U.S. market as it has elsewhere. McBrayer highlights the technology's unique, efficient, and versatile applications and notes extensive interest and support from U.S. clinicians. He outlines Cyclopharm's readiness for increased production and potential for robust revenue from consumable sales, maintaining the company's Australian domicile while considering future options.

Jesse Moors of Spatium Capital highlights the significant trend shift happening among Australian small-cap companies after a two-year stagnation period. Jesse points out that around the globe, smaller sectors typically exceed their larger counterparts by approximately 1.5 to 2.5 or even 3 percent annually over an extended period, because they are vying for a larger market share. He takes note of the struggles faced by Australian small sectors in the first quarter of 2022, yet underlines a remarkable recovery in subsequent months. Despite market variability, Jesse holds fast to his investment strategy whereby he takes advantage of short-term divergence to pinpoint companies whose costs have substantially deviated from the industry or market averages, a concept he likens to the 'return to the mean' similar to planet orbits. Included in his approach is a semi-manual Quantitative Investment Strategy, rather than solely automatic, leveraging the intrinsic volatility and ambiguity of small-cap stocks to generate distinct results.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy